Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490223 | 0.99 | CA1 (0.55) | CA1CA2ALDH1A1TP53ALDH3A1 | |
| SCHEMBL490225 | 0.99 | CA1 (0.55) | CA1CA2ALDH1A1TP53ALDH3A1 | |
| SCHEMBL3911160 | 0.89 | ALDH3A1 (0.59) | CA1CA2ALDH1A1ALDH3A1BCHE | |
| SCHEMBL3911162 | 0.89 | ALDH3A1 (0.59) | CA1CA2ALDH1A1ALDH3A1BCHE | |
| SCHEMBL3986882 | 0.89 | ALDH1A1 (0.59) | CA1CA2ALDH1A1ALDH3A1BCHE | |
| SCHEMBL3986887 | 0.89 | ALDH1A1 (0.59) | CA1CA2ALDH1A1ALDH3A1BCHE | |
| SCHEMBL3911110 | 0.80 | KDR (0.48) | ALDH1A1TP53KDRRETPDGFRB | |
| SCHEMBL3911113 | 0.80 | KDR (0.48) | ALDH1A1TP53KDRRETPDGFRB | |
| SCHEMBL5817331 | 0.78 | CA1 (0.50) | CA1CA2ALDH1A1TP53ALDH3A1 | |
| SCHEMBL5817327 | 0.78 | CA1 (0.50) | CA1CA2ALDH1A1TP53ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331546-B1 | CXCR4 INHIBITOR FOR THE TREATMENT OF CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2023-10-04 | — | — | EP | disclosed |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2018-08-09 | — | — | US | disclosed |
| WO-2017021963-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | BIOKINE THERAPEUTICS LTD. (IL) | 2017-02-09 | — | — | WO | disclosed |
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | CA1 889/4885CA2 231/4885ALDH1A1 3813/4885 |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | CA1 889/4885CA2 231/4885ALDH1A1 3813/4885 |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | CA1 889/4885CA2 231/4885ALDH1A1 3813/4885 |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | BAK1, BCL2, BCL3 | CA1 889/4885CA2 231/4885ALDH1A1 3813/4885 |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | CXCL12, CXCR4, CXCR1 | CA1 3303/4885CA2 3875/4885ALDH1A1 2395/4885 |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | CA1 870/4885CA2 224/4885ALDH1A1 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.